Melissa O’Gorman - Concepedia

Author

Melissa O’Gorman

Also Known As

H Shi, M O'Gorman, M. O'Gorman, Melissa O'Gorman, Melissa O’Gorman, Melissa T O'Gorman, Melissa T. O'Gorman, Melissa T. O’Gorman

Publications

801

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Pfizer (Italy)

About

Melissa O’Gorman is an author at Pfizer (United States) specializing in pharmacology, medicine, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	381
2	Biochemistry	3	3	152
3	Diabetes	3	3	152
4	Health Sciences	2	2	93
5	Natural Sciences	2	2	84

Melissa O’Gorman

Publications

716

Citations

H-Index

Page 1

	Year	Citations
Impact of Acid‐Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH‐Dependent Solubility, With Different Food Intake Conditions Wan Sun, Karen J. Klamerus, Lisa M. Yuhas, Clinical Pharmacology in Drug Development	2017	77
A Highly Selective, Non-Hydantoin, Non-Carboxylic Acid Inhibitor of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models: 6-(5-Chloro-3-methylbenzofuran- 2-sulfonyl)-2-<i>H</i>-pyridazin-3-one Banavara L. Mylari, Sandra J. Armento, David A. Beebe, Journal of Medicinal Chemistry Oral BioavailabilityAldo-keto ReductaseGlycobiologyMetabolic SyndromePotent Oral Activity	2003	68
A Novel Series of Non-Carboxylic Acid, Non-Hydantoin Inhibitors of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models: 6-(5-Chloro-3-methylbenzofuran-2-sulfonyl)-2<i>H</i>-pyridazin-3-one and Congeners Banavara L. Mylari, Sandra J. Armento, David A. Beebe, Journal of Medicinal Chemistry Medicinal ChemistryAldo-keto ReductaseBiochemistryMedicineAldose Reductase	2005	65
Metabolism, excretion and pharmacokinetics of [<sup>14</sup>C]crizotinib following oral administration to healthy subjects Theodore R. Johnson, Weiwei Tan, Lance Goulet, Xenobiotica	2014	56
The Bioequivalence of Tafamidis 61‐mg Free Acid Capsules and Tafamidis Meglumine 4 × 20‐mg Capsules in Healthy Volunteers Peter Lockwood, Vu Le, Melissa O’Gorman, Clinical Pharmacology in Drug Development Tafamidis Meglumine 4Therapeutic Drug MonitoringTafamidis 61‐MgMedicineTafamidis Meglumine	2020	52
The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus Vaishali Sahasrabudhe, Steven G. Terra, A. Hickman, The Journal of Clinical Pharmacology	2017	47
Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects Huiping Xu, Melissa O’Gorman, Tanya Boutros, The Journal of Clinical Pharmacology NutritionHealthy SubjectsPic FormulationsPathologyPharmacotherapy	2014	44
Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites Ellen Q. Wang, Vu Le, Melissa O’Gorman, The Journal of Clinical Pharmacology	2021	38
The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects Huiping Xu, Melissa O’Gorman, Weiwei Tan, European Journal of Clinical Pharmacology Healthy SubjectsPharmacological StudyMedicineClinical PharmacologyPharmacotherapy	2015	35
Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study Joseph Chen, Melissa O’Gorman, Lee P. James, Clinical Pharmacokinetics	2021	34

Page 1